-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 Pvp3sdRLgEXXnMWKrVj7kj7dlzi2mFrob8kcmKeI5j254XL4HjLo2n2kb2Fd3cuM
 l1wvXXiprDjd2dCusdwR3w==

<SEC-DOCUMENT>0001279569-09-000149.txt : 20090204
<SEC-HEADER>0001279569-09-000149.hdr.sgml : 20090204
<ACCEPTANCE-DATETIME>20090204133439
ACCESSION NUMBER:		0001279569-09-000149
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20090204
FILED AS OF DATE:		20090204
DATE AS OF CHANGE:		20090204

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOLYTICS BIOTECH INC
		CENTRAL INDEX KEY:			0001129928
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-31062
		FILM NUMBER:		09567692

	BUSINESS ADDRESS:	
		STREET 1:		1167 KENSINGTON CRES NW SUITE 210
		STREET 2:		CALGARY ALBERTA CANADA T2N 1X7
		CITY:			ALBERTA CANADA
		STATE:			A0
		ZIP:			00000
		BUSINESS PHONE:		4036707380

	MAIL ADDRESS:	
		STREET 1:		210 - 1167 KENSINGTON CRES NW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2N 1X7
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>oncolytics6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<html>
  <head>
    <title>oncolytics6k.htm</title>
<!-- Licensed to: CNW Group-->
<!-- Document Created using EDGARizer 4.0.6.4 -->
<!-- Copyright 1995 - 2008 EDGARfilings, Ltd., an IEC company. All rights reserved -->
</head>
    <body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><!--
    PAGEBREAK -->
&#160;

    <div style="FONT-FAMILY: 'Times New Roman',Times,serif">
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
      <hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
      <div style="FONT-SIZE: 14pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman"><font style="FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">SECURITIES AND<font size="+0" style="FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman"> EXCHANGE</font>
COMMISSION</font><br></font></font></font></font><font style="FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">Washington, D.C.
20549</font></div>
      <div style="FONT-SIZE: 12pt" align="center">&#160;</div>
      <div style="FONT-SIZE: 18pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman">F<font size="+0" style="FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman">orm</font>
6-K</font></div>
      <div>&#160;</div>
      <div style="FONT-SIZE: 10pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">Report
of Foreign Private Issuer</font></div>
      <div>&#160;</div>
      <div style="FONT-SIZE: 10pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><font size="+0">Pursuant to Rule</font>&#160;13a-16 or 15d-16<br>of the Securities
Exchange Act of 1934</font></div>
      <div>&#160;</div>
      <div style="FONT-SIZE: 10pt" align="center">For the month of&#160;February 2009
</div>
      <div>&#160;</div>
      <div style="FONT-SIZE: 10pt" align="center">Commission File Number 000-31062
</div>
      <div>&#160;</div>
      <center>
        <div style="FONT-SIZE: 24pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 24pt; FONT-FAMILY: Times New Roman">Onc<font size="+0" style="FONT-SIZE: 24pt; FONT-FAMILY: Times New Roman">oly</font>tics
Biotech Inc.</font></div>
        <hr style="COLOR: black" align="center" noshade size="1" width="45%">
        <div style="FONT-SIZE: 10pt" align="center"><font style="DISPLAY: inline; FONT-STYLE: italic">(Translation of registrant&#8217;s name
into English)</font></div>
        <div style="FONT-SIZE: 10pt" align="center">&#160;</div>
      </center>
      <center>
        <div style="FONT-SIZE: 10pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Suite&#160;210, 1167 Kensington
Crescent NW<br>Calgary, Alberta, Canada T2N 1X7</font></div>
        <hr style="COLOR: black" align="center" noshade size="1" width="45%">
        <div style="FONT-SIZE: 10pt" align="center"><font style="DISPLAY: inline; FONT-STYLE: italic">(Address of principal executive
offices)</font></div>
        <div style="FONT-SIZE: 10pt" align="center">&#160;</div>
      </center>
      <div style="FONT-SIZE: 10pt">Indicate by check mark whether the registrant files
or will file annual reports under cover Form&#160;20-F or Form&#160;40-F. </div>
      <center>
        <div>
          <table border="0" cellpadding="0" cellspacing="0" width="70%" style="FONT-SIZE: 10pt">
              <tr valign="bottom">
                <td width="49%">&#160;</td>
                <td width="2%">&#160;</td>
                <td width="49%">&#160;</td>
              </tr>
              <tr valign="bottom">
                <td valign="top">
                  <div style="TEXT-ALIGN: center">Form&#160;20-F&#160;&#160;&#160;<font style="FONT-FAMILY: wingdings">&#254;</font></div>
                </td>
                <td>&#160;</td>
                <td valign="top">
                  <div style="TEXT-ALIGN: center">Form&#160;40-F&#160;&#160;&#160;<font style="FONT-FAMILY: wingdings">o</font></div>
                </td>
              </tr>
          </table>
        </div>
      </center>
      <div style="FONT-SIZE: 10pt">&#160;</div>
      <div style="FONT-SIZE: 10pt">Indicate by check mark if the registrant is
submitting the Form&#160;6-K in paper as permitted by Regulation&#160;S-T
Rule&#160;101(b)(1):&#160;&#160;&#160;<font style="FONT-FAMILY: wingdings">o</font></div>
      <div>&#160;</div>
      <div style="FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Note: </font>Regulation&#160;S-T
Rule&#160;101(b)(1) only permits the submission in paper of a Form&#160;6-K if
submitted solely to provide an attached annual report to security holders.
</div>
      <div>&#160;</div>
      <div style="FONT-SIZE: 10pt">Indicate by check mark if the registrant is
submitting the Form&#160;6-K in paper as permitted by Regulation&#160;S-T
Rule&#160;101(b)(7):&#160;&#160;&#160;<font style="FONT-FAMILY: wingdings">o</font></div>
      <div>&#160;</div>
      <div style="FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Note: </font>Regulation&#160;S-T
Rule&#160;101(b)(7) only permits the submission in paper of a Form&#160;6-K if
submitted to furnish a report or other document that the registrant foreign
private issuer must furnish and make public under the laws of the jurisdiction
in which the registrant is incorporated, domiciled or legally organized (the
registrant&#8217;s &#8220;home country&#8221;), or under the rules of the home country exchange on
which the registrant&#8217;s securities are traded, as long as the report or other
document is not a press release, is not required to be and has not been
distributed to the registrant&#8217;s security holders, and, if discussing a material
event, has already been the subject of a Form&#160;6-K submission or other
Commission filing on EDGAR. </div>
      <div>&#160;</div>
      <div style="FONT-SIZE: 10pt">Indicate by check mark whether by furnishing the
information contained in this Form, the registrant is also thereby furnishing
the information to the Commission pursuant to Rule&#160;12g3-2(b) under the
Securities Exchange Act of 1934. </div>
      <center>
        <div>
          <table border="0" cellpadding="0" cellspacing="0" width="70%" style="FONT-SIZE: 10pt">
              <tr valign="bottom">
                <td width="49%">&#160;</td>
                <td width="2%">&#160;</td>
                <td width="49%">&#160;</td>
              </tr>
              <tr valign="bottom">
                <td valign="top">
                  <div style="TEXT-ALIGN: center">Yes&#160;&#160;&#160;<font style="FONT-FAMILY: wingdings">o</font></div>
                </td>
                <td>&#160;</td>
                <td valign="top">
                  <div style="TEXT-ALIGN: center">No&#160;&#160;&#160;<font style="FONT-FAMILY: wingdings">&#254;</font></div>
                </td>
              </tr>
          </table>
        </div>
      </center>
      <div style="FONT-SIZE: 10pt">&#160;</div>
      <div style="FONT-SIZE: 10pt">If &#8220;Yes&#8221; is marked, indicate below the file number
assigned to the registrant in connection with
Rule&#160;12g3-2(b):&#160;&#160;&#160;82&#160;-&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div>
      <div>&#160;</div>
      <div>
      </div>
      <div>&#160;</div>
      <hr style="MARGIN-TOP: -2px; COLOR: #000000" noshade size="1">
      <hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="4">
      <div style="FONT-SIZE: 10pt">
      </div>
      <div>&#160;</div>
    </div><!-- PAGEBREAK -->

    <div>
    </div>
    <div>&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div align="left">&#160;</div>
    <div>
    </div>
    <div>
    </div>
    <div>
      <div>
        <div align="left">
          <div align="left">
            <div align="left">
              <div align="left">
                <table cellpadding="0" cellspacing="0" width="100%">
                    <tr>
                      <td align="left" valign="bottom" width="6%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">EXHIBIT</font></div>
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">NUMBER</font></div>
                      </td>
                      <td valign="bottom" width="2%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                      <td valign="bottom" width="68%" style="BORDER-BOTTOM: black 2px solid">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">DESCRIPTION</font></div>
                      </td>
                    </tr>
                    <tr>
                      <td valign="top" width="6%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                      <td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                      <td valign="top" width="68%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" width="6%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">99.1</font></div>
                      </td>
                      <td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                      <td align="left" valign="top" width="68%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: times new roman, serif"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">News Release Dated
      February 4, 2009 -</font> Cancer Therapy &amp; Research Center at The
      University of Texas Health Science Center and Oncolytics Biotech(R) Inc.
      Announce Multi-Trial Clinical Research
      Collaboration</font></font></font></div>
                      </td>
                    </tr>
                </table>
              </div>
            </div>
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    </div>
    <div>&#160;</div>
    <div>&#160;</div>
    <div>&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div>&#160;</div>
    <div style="FONT-FAMILY: 'Times New Roman',Times,serif">
      <div style="FONT-SIZE: 10pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold">SIGNATURES</font></div>
      <div>&#160;</div>
      <div style="FONT-SIZE: 10pt">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized. </div>
      <div>&#160;</div>
      <center>
        <div>
          <table border="0" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt">
              <tr valign="bottom">
                <td width="50%">&#160;</td>
                <td width="1%">&#160;</td>
                <td width="1%">&#160;</td>
                <td width="1%">&#160;</td>
                <td width="47%">&#160;</td>
              </tr>
              <tr valign="bottom">
                <td valign="top">&#160;</td>
                <td>&#160;</td>
                <td align="left" colspan="3" valign="top"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Oncolytics Biotech
      Inc.</font><br>(Registrant)</td>
              </tr>
              <tr>
                <td>&#160;</td>
              </tr>
              <tr valign="bottom">
                <td valign="top">&#160;</td>
                <td>&#160;</td>
                <td align="left" valign="top">&#160;</td>
                <td>&#160;</td>
                <td align="left" valign="top">&#160;</td>
              </tr>
              <tr>
                <td>&#160;</td>
              </tr>
              <tr valign="bottom">
                <td valign="top">Date:&#160;&#160;February 4, 2009 </td>
                <td>&#160;</td>
                <td align="left" valign="top">By:</td>
                <td>&#160;</td>
                <td align="left" valign="top">/s/&#160;&#160;Doug Ball

                  <hr style="COLOR: black" align="left" noshade size="1" width="60%">      Doug Ball<br>Chief Financial Officer</td>
              </tr>
          </table>
        </div>
      </center>
      <div style="FONT-SIZE: 10pt" align="center">
      </div>
      <div>&#160;</div>
    </div><!-- PAGEBREAK -->
</body>
</html>


</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex991.htm
<DESCRIPTION>NEWS RELEASE DATED FEBRUARY 4, 2009
<TEXT>
<html>
  <head>
    <title>ex991.htm</title>
<!-- Licensed to: CNW Group-->
<!-- Document Created using EDGARizer 4.0.6.4 -->
<!-- Copyright 1995 - 2008 EDGARfilings, Ltd., an IEC company. All rights reserved -->
</head>
    <body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
    <pre>Exhibit 99.1</pre>
    <pre>News release via Canada NewsWire, Toronto 416-863-9350

	    Attention Business Editors:
	    Cancer Therapy &amp; Research Center at The University of Texas Health
	    Science Center and Oncolytics Biotech(R) Inc. Announce Multi-Trial
	    Clinical Research Collaboration

	    CALGARY, Feb. 4 /CNW/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC,
NASDAQ:ONCY) and the Cancer Therapy &amp; Research Center at The University of
Texas Health Science Center in San Antonio, (CTRC at UTHSCSA) announced a
broad preclinical and clinical collaboration involving up to five, open-label,
Phase 2 studies exploring the use of REOLYSIN(R) in combination with
chemotherapy for various cancer indications. These indications are expected to
include melanoma, pancreatic cancer, squamous cell lung, liver and K-RAS
mutated colorectal cancers in combination with standard chemotherapeutics.
This research program is in addition to Phase 2 trials in sarcoma and
refractory head &amp; neck cancers, sponsored by Oncolytics that are currently
underway at this site.
	    "As an NCI-designated cancer center, we give a very high priority to
approaches that are likely to significantly improve the prognosis of patients
with malignant diseases," said Dr Giles, Deputy Director of the CTRC at
UTHSCSA. "As Director of our Institute for Drug Development (IDD), I am
pleased to specifically dedicate IDD resources toward the further rapid
investigation of REOLYSIN(R), an agent which is proving itself in the clinic."
	    "We're excited that an institution of this caliber is investing in
additional research opportunities for REOLYSIN(R)," said Dr. Karl Mettinger,
Chief Medical Officer of Oncolytics. "This comprehensive research program will
explore additional opportunities for REOLYSIN(R) in cancer treatment, while
allowing the Company to focus its resources on developing its pivotal
program."

	    About Oncolytics Biotech Inc.

	    Oncolytics is a Calgary-based biotechnology company focused on the
development of oncolytic viruses as potential cancer therapeutics.
Oncolytics' clinical program includes a variety of Phase I and Phase II human
trials using REOLYSIN(R), its proprietary formulation of the human reovirus,
alone and in combination with radiation or chemotherapy. For further
information about Oncolytics, please visit www.oncolyticsbiotech.com

	    About CTRC at UTHSCSA

	    The CTRC at the UT Health Science Center serves more than 4.4 million
people in the high-growth corridor of South and Central Texas, including San
Antonio, Austin, Laredo and the Rio Grande Valley. It handles more than
120,000 patient visits each year. The mission of the CTRC at the UT Health
Science Center is to promote interdisciplinary research in cancer-related
areas of basic science, clinical research, and cancer prevention and control,
and to foster the application of the results of that research in the community
setting, especially in the South Texas community. The CTRC Institute for Drug
Development (IDD) is internationally recognized for conducting the largest
oncology Phase I clinical research studies program in the world. In a Phase I
research study, a new agent for cancer is tested in human patients for the
first time. Fifteen of the cancer drugs most recently approved by the U.S.
Food and Drug Administration underwent development or testing at the IDD.

	    This press release contains forward-looking statements, within the
meaning of Section 21E of the Securities Exchange Act of 1934, as amended.
Forward-looking statements, including the Company's expectations related to
the CTRC at UTHSCSA-sponsored trials, and the Company's belief as to the
potential of REOLYSIN(R) as a cancer therapeutic, involve known and unknown
risks and uncertainties, which could cause the Company's actual results to
differ materially from those in the forward-looking statements. Such risks and
uncertainties include, among others, the availability of funds and resources
to pursue research and development projects, the efficacy of REOLYSIN(R) as a
cancer treatment, the tolerability of REOLYSIN(R) outside a controlled test,
the success and timely completion of clinical studies and trials, the
Company's ability to successfully commercialize REOLYSIN(R), uncertainties
related to the research and development of pharmaceuticals and uncertainties
related to the regulatory process. Investors should consult the Company's
quarterly and annual filings with the Canadian and U.S. securities commissions
for additional information on risks and uncertainties relating to the forward
looking statements. Investors are cautioned against placing undue reliance on
forward-looking statements. Information about CTRC at the UT Health Science
Center was provided by CTRC. The Company does not undertake to update these
forward-looking statements, except as required by applicable laws.

	    %SEDAR: 00013081E          %CIK: 0001130319

	    /For further information: Oncolytics Biotech Inc.: Cathy Ward, 210, 1167
Kensington Cr NW, Calgary, Alberta, T2N 1X7, Tel: (403) 670-7377, Fax: (403)
283-0858, cathy.ward(at)oncolytics.ca; The Equicom Group: Nick Hurst, 325, 300
5th Ave. SW, Calgary, Alberta, T2P 3C4, Tel: (403) 538-4845, Fax: (403)
237-6916, nhurst(at)equicomgroup.com; The Investor Relations Group: Erika Moran,
11 Stone St, 3rd Floor, New York, NY, 10004, Tel: (212) 825-3210, Fax: (212)
825-3229, emoran(at)investorrelationsgroup.com/
	    (ONC. ONCY)

CO:  Oncolytics Biotech Inc.

CNW 12:15e 04-FEB-09

</pre>
  </body>
</html>


</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
